Geode Capital Management LLC Grows Stake in LivaNova PLC $LIVN

Geode Capital Management LLC lifted its position in LivaNova PLC (NASDAQ:LIVN) by 0.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,458,838 shares of the company’s stock after purchasing an additional 12,750 shares during the period. Geode Capital Management LLC’s holdings in LivaNova were worth $89,775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of LivaNova by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after buying an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in LivaNova by 4.6% during the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after buying an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in LivaNova by 10.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after buying an additional 15,405 shares during the last quarter. Intech Investment Management LLC increased its holdings in LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after buying an additional 7,195 shares during the last quarter. Finally, Strs Ohio purchased a new stake in LivaNova during the first quarter valued at approximately $130,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LivaNova stock opened at $72.36 on Monday. LivaNova PLC has a one year low of $41.01 and a one year high of $75.82. The stock’s fifty day moving average is $67.58 and its 200 day moving average is $65.02. The stock has a market cap of $3.97 billion, a P/E ratio of 37.11 and a beta of 0.88. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same period last year, the firm earned $0.88 EPS. LivaNova’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on LIVN. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho raised their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Barclays raised their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Needham & Company LLC raised their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is currently owned by corporate insiders.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.